-FAPI-74 not checked

Actithera INC.

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 1/2 trial completes
Trials
1 active
1 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
FAP-expressing Solid Tumors, Pancreatic Ductal Adenocarcinoma (PDAC), Biliary Tract Carcinoma (BTC)
Main trialPhase 1/2
“This is a study of 177Lu -ACT319 in participants with the following cancers: pancreatic ductal adenocarcinoma (PDAC), biliary tract carcinoma (BTC), that is advanced, and for which there are no valid treatment options. Participants must have cancer that expresses protein called fibroblast activation protein (FAP). The purpose of this study is to evaluate safety, how the body tolerates, and how well ACT319 works in treating cancer. In addition, this study will evaluate how much 177Lu-ACT319 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. For…”In the company’s words, NCT07941362 on ClinicalTrials.gov

Other drugs for Pancreatic Ductal Adenocarcinoma (PDAC)

All 201 drugs for Pancreatic Ductal Adenocarcinoma (PDAC)

Coming up1

Changes1

Last 90 days

Trials1

TrialPhaseCompletesWhat it tests
Phase 1/2Not yet recruiting 31 Jul 2029 177Lu-ACT319 in FAP Expressing Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 20 Nov 2026 · EU trials register (CTIS) updated 20 Nov 2026 · openFDA updated 20 Nov 2026

Follow -FAPI-74

Following is part of Solo: you see every change to -FAPI-74 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in